This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated BATF3 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-BATF3 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~14.5 kDa | |
| Gel | 15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
| PTM | Phosphorylated | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
The A01957 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | mouse-lung mouse-spleen lysis (catalog A01957) |
| Gel % | 15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.2 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A01957; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | 1:20000 (catalog A01957) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
BATF3 is predicted at 14.5 kDa; phosphorylation could affect migration, but no distinct band position has been demonstrated.
| Band near 14.5 kDa | consistent with the predicted size of BATF3; confirm identity with antibody controls |
| Close doublet near 14.5 kDa | could reflect phosphorylation at Ser2 or Ser31, but distinct migration is unproven |
| Weak band in cytoplasmic fraction | consistent with BATF3 localization to the nucleus |
| Stronger band in nuclear fraction | consistent with nuclear enrichment of BATF3 |
| UniProt predicted mass | sets a 14.5 kDa reference for the full-length protein |
| 127-amino-acid sequence | underlies the predicted full-length mass; no processed size is specified |
| Ser2 phosphorylation | may alter migration, but no measurable shift is supplied |
| Ser31 phosphorylation | may alter migration, but no measurable shift is supplied |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | BATF3 is nuclear and may be underrepresented in the preparation | check a nuclear extract and confirm fraction quality |
| Band higher than expected | phosphorylation at Ser2 or Ser31 may affect migration, but its effect is unmeasured | compare phosphatase-treated and untreated samples with identity controls |
| Band lower than expected | the supplied features do not establish a smaller BATF3 product | check antibody specificity and compare with full-length BATF3 |
| Multiple bands | phosphorylation may produce distinct states, but their separation is unproven | compare phosphatase-treated samples and verify band identity |
| Weak or no signal | a cytoplasmic preparation may contain little nuclear BATF3 | test a nuclear extract and verify extraction quality |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Deeper troubleshooting and optimisation questions for BATF3, answered from its protein features.
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
The catalog reports one anti-BATF3 antibody, A01957, with reported human, mouse, and rat reactivity. Its Western blot image shows mouse lung and spleen lysates at a 1:2000 primary antibody dilution; the supplied image does not show human or rat samples.
Which to pick: A01957 is the only listed option. Its supplied Western blot image uses mouse lung and spleen lysates, so those are the directly illustrated sample contexts. Human and rat reactivity is listed but not shown in the supplied image.